Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects
Manza P, Amandola M, Tatineni V, Li CR, Leung HC. Response inhibition in Parkinson’s disease: a meta-analysis of dopaminergic medication and disease duration effects. Npj Parkinson's Disease 2017, 3: 23. PMID: 28702504, PMCID: PMC5501877, DOI: 10.1038/s41531-017-0024-2.Peer-Reviewed Original ResearchDopamine replacement therapyEarly-stage Parkinson's diseaseDisease durationParkinson's diseaseDopaminergic medicationDopaminergic drugsDisease patientsResponse inhibitionCognitive functionDisease duration effectHallmark motor symptomsParkinson's disease durationShorter disease durationAdvanced Parkinson's diseaseParkinson's disease patientsRole of dopamineResponse inhibition deficitsMotor symptomsBasal gangliaHealthy controlsMedication statusMedicationsPatientsCognitive deficitsNeurodegenerative disorders